Government-funded project of the Ministry of Trade, Industry and Energy 'Mid-sized Enterprise Synergy Innovation Project'

Blood analyzer applying AI deep learning technology, jointly developed with the National Cancer Center

Synopex announced that it has successfully completed the government-funded project (Project name: Development of General Blood Diagnosis and Blood Cancer Cell Analysis System using Peripheral Blood based on Edge Computing) of the Ministry of Trade, Industry and Energy's 'Mid-sized Enterprise Synergy Innovation Project'.

Synopex announced that it had presented the results of the development at the final evaluation committee of the Mid-sized Enterprise Synergy Innovation Project and received a notification from the Korea Institute for Industrial Economics and Trade that the project had been completed.

This government-funded project was conducted as a project of the Ministry of Trade, Industry and Energy's 'Mid-sized Enterprise Synergy Innovation Project' in 2022, with Synopex as the leading company and the National Cancer Center and Health Connect as co-research and development institutions.

Through this project, Synopex has developed △ a hematology analyzer (model name Lumiio) and △ a cartridge applying Lab-on-a-Chip technology, and the hematology analyzer was registered as a Class 1 in vitro diagnostic device of the Ministry of Food and Drug Safety's automatic hematology counter (product approval number: in vitro diagnostic 24-92) in January this year.

In particular, Synopex announced that it has filed for patents for 6 new technologies applied to this blood analysis system.

The hematology analyzer (Lumiio) developed by Synopex is a compact product measuring approximately 15 centimeters in width, height, and depth, weighing 1.23 kg, and is a professional product that can be used in hospitals.

Lumiio developed by Synopex is characterized by its application of its own refraction optics technology and AI implementation.

Lumiio, equipped with AI, can monitor diseases such as inflammatory diseases, platelet diseases, anemia, and infections through morphological analysis of blood cells based on data learned through deep learning, and provides basic data for diagnosing blood cancers such as leukemia and lymphoma through abnormal blood cell analysis.

In addition, the cartridge applying Lab-on-a-Chip technology is a revolutionary product that can perform the four steps of blood smear, drying, staining, and washing, which are required for general manual blood analysis, through a disposable cartridge.

In particular, Synopex announced that it has successfully developed a vibration-type micro-pump that dramatically reduces costs by replacing expensive micro-pumps required for cartridges, enabling the use of disposable cartridges.

Dr. Min-Chul Hong, Head of Synopex's Artificial Kidney R&D Center, said, “Based on the success of this government-funded project, we plan to further upgrade the cartridge applying Lab-on-a-Chip technology by the end of this year to secure mass production capacity and improve its completion level, and we will expand the types of diseases that can be analyzed with blood and improve accuracy." He added, "We aim to contribute to improving the health of citizens and reducing medical costs through early diagnosis of serious diseases with a revolutionary system that enables blood diagnosis as well as morphological analysis data of blood in just 10 minutes with a single drop of blood (30 μL), and data can be transmitted to a mobile phone or printed out."

Synopex aims to strengthen its medical device business competitiveness and grow into a global company through the synergy of its ongoing blood dialysis business and blood diagnosis business, which enables health management and early diagnosis of serious diseases.

Website: http://www.synopex.com

Contact
Synopex
IR Team
Won-Chul Choi, Pro
031-379-7777